Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 10;4(3):186-192.
doi: 10.1016/j.wjorl.2018.09.002. eCollection 2018 Sep.

Immunomodulators in chronic rhinosinusitis

Philippe Lavigne  1 , Stella E Lee  1   2
Affiliations
Review

Immunomodulators in chronic rhinosinusitis

Philippe Lavigne et al. World J Otorhinolaryngol Head Neck Surg. .

Abstract

Objective: To provide new insight into how chronic rhinosinusitis (CRS) is conceptualized and treated with a focus on immunomodulator therapy.

Data sources: Pubmed, Medline, and Embase.

Methods: A current review of the evidence is provided for immunomodulators investigated for treatment of CRS with nasal polyps (CRSwNP).

Results: Biologic therapies targeting IgE, IL-4, IL-5, and IL-13 for the treatment of CRSwNP have shown promise and are currently in phase 3 trials. Anti-immunoglobin E (IgE) therapy with omalizumab was assessed in 6 studies, anti-interleukin (IL)-5 therapy in 3 studies (2 mepolizumab, 1 reslizumab) and anti IL-4/IL-13 (dupilumab) therapy in one study. Studied outcomes varied, but the majority of trials identified clinical benefit of therapy over placebo. Other potential targets include thymic stromal lymphopoetin (TSLP), IL-25, IL-33, and sialic acid-binding immunoglobulin-type lectin (Siglec)-8. Small molecule drugs that target the dysregulation of the immune system in CRS are also being investigated for their immunomodulatory effects on inflammation.

Conclusion: Immunomodulator therapies for CRS currently in development will likely provide another therapeutic option for patients who have severe disease unresponsive to corticosteroids and surgery. Targeted monoclonal antibody therapies have shown encouraging results and phase 3 trials are underway. IL-4/IL-13 inhibition has shown the most promise to date. Further larger, well-designed trials are needed to improve understanding of these molecules and to offer endotype-driven therapies in the management of CRS. None of these therapeutics have shown long-term immunomodulation when discontinued and therefore further investigation into the pathomechanism of disease continues to be needed.

Keywords: Biologic; Chronic rhinosinusitis; Immunomodulator; Immunotherapy; Nasal polyps.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CT scan of one patient before and after therapy of dupilumab. A: before therapy; B: after therapy.
See this image and copyright information in PMC

References

    1. Hastan D., Fokkens W.J., Bachert C. Chronic rhinosinusitis in Europe--an underestimated disease. A GA2LEN study. Allergy. 2011;66:1216–1223. - PubMed
    1. Schiller J.S., Lucas J.W., Peregoy J.A. Summary health statistics for U.S. adults: national health interview survey, 2011. Vital Health Stat. 2012;10:1–218. - PubMed
    1. Shi J.B., Fu Q.L., Zhang H. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy. 2015;70:533–539. - PMC - PubMed
    1. Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372:1107–1119. - PubMed
    1. DeConde A.S., Mace J.C., Levy J.M., Rudmik L., Alt J.A., Smith T.L. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127:550–555. - PMC - PubMed

LinkOut - more resources